Author: De Jong, Cornelis N.; Saes, Lotte; Klerk, Clara P. W.; Van der Klift, Marjolein; Cornelissen, Jan J.; Broers, Annoek E. C.
Title: Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience Document date: 2017_10_26
ID: 1hcp36cw_10
Snippet: Once SR-aGVHD was established, second-line treatment with etanercept was initiated, in addition to first-line therapy. Etanercept (Enbrel, Pfizer) was administered subcutaneously twice weekly at a dose of 25 mg for an intended period of eight weeks......
Document: Once SR-aGVHD was established, second-line treatment with etanercept was initiated, in addition to first-line therapy. Etanercept (Enbrel, Pfizer) was administered subcutaneously twice weekly at a dose of 25 mg for an intended period of eight weeks.
Search related documents:
Co phrase search for related documents- etanercept second line treatment and second line: 1, 2, 3, 4, 5, 6, 7, 8
- etanercept second line treatment and second line treatment: 1, 2, 3, 4, 5, 6, 7, 8
- intended period and line therapy: 1
- line therapy and second line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- line therapy and second line treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Co phrase search for related documents, hyperlinks ordered by date